January 28, 2010 - Therapeutic Temperature Management Contract with HealthTrust Purchasing Group INVESTOR CONTACT: A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655 MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) firstname.lastname@example.org ZOLL AWARDED THERAPEUTIC TEMPERATURE MANAGEMENT CONTRACT WITH HEALTHTRUST PURCHASING GROUP January 28, 2010─CHELMSFORD, MASS.–. ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that HealthTrust Purchasing Group, LP (HealthTrust), a leading healthcare group purchasing organization (GPO), has entered into a purchasing agreement with ZOLL for its therapeutic temperature management equipment. Under the terms of the agreement, HealthTrust members will be able to purchase ZOLL’s intravascular temperature management (IVTM™) system, which includes the Thermogard XP® temperature management console and a family of cooling/warming catheters with triple lumen central venous capability. “We are extremely pleased that this large group purchasing organization, which has very high member commitment to buying products under its contracts, recognizes the advantages of our IVTM solution, and is offering its members the opportunity to incorporate this technology to improve the treatment of critical care patients,” said Richard A. Packer, Chairman and CEO of ZOLL. Today, major medical societies recommend temperature management as the standard of care treatment for many critically ill or surgical patients. IVTM provides cooling and warming from a catheter inserted into the patient’s vein. This provides better control of the core body temperature by direct cooling or warming the patient’s blood as it circulates through the body. Since it is efficient, precise and easy to use, IVTM frees up nursing time. IVTM provides a variety of catheter options depending upon the specific patient needs. It is ideally suited for the temperature management of fever, intracranial pressure control and induced hypothermia. IVTM is also effective for therapeutic warming as required in treating trauma, burns, perioperative procedures and accidental hypothermia. Additionally, recent publications have described cost reductions for hospital systems, based upon the reduced length of stay in the ICU with the implementation of aggressive fever management protocols. About HealthTrust Purchasing Group HealthTrust Purchasing Group, headquartered in Brentwood, Tenn., is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than $15 billion, HealthTrust is committed to obtaining the best price for clinically recommended products, ensuring their timely delivery, and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. The web site is www.healthtrustpg.com. About ZOLL Medical Corporation ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 10, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements. Copyright © 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and Thermogard XP are registered trademarks of ZOLL Medical Corporation. IVTM is a trademark of ZOLL Medical Corporation. All product names are the property of their respective owners.